Zevra Therapeutics Q2 revenue beats estimates
Overview
Zevra Q2 2025 net revenue rises to $25.9 mln, beating analyst expectations
Net income for Q2 2025 reaches $74.7 mln, surpassing analyst estimates
Co completed $150 mln PRV sale, strengthening financial position
Outlook
Zevra plans to expand MIPLYFFA benefits to more patients in Europe
Company believes it has sufficient resources for strategic priorities without capital markets
Result Drivers
MIPLYFFA REVENUE - Generated $21.5 mln in net revenue, driving overall revenue growth
PRV SALE - Completed sale for $150 mln, bolstering financial position
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $25.88 mln | $22.50 mln (7 Analysts) |
Q2 Net Income | Beat | $74.71 mln | $61.10 mln (4 Analysts) |
Q2 Income from Operations | Miss | -$71.04 mln | -$4.39 mln (5 Analysts) |
Q2 Pretax Profit | Beat | $76.91 mln | $54.10 mln (5 Analysts) |
Q2 Operating Expenses |
| $24.22 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Zevra Therapeutics Inc is $25.00, about 53.2% above its August 11 closing price of $11.70
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 23 three months ago
Press Release: ID:nGNX6Hxckz
Related Articles
Applied Materials Q3 Earnings: AI Demand Soars, but Cautious Guidance Triggers After-Hours Selloff
TradingKey - Applied Materials, Inc. (NASDAQ: AMAT) announced its Q3 FY2025 earnings on August 14, 2025, after market close, reporting strong revenue fueled by AI-related semiconductor demand, which beat expectations. However, cautious Q4 guidance, including EPS below analyst estimates.jpg)
The Market Game of the Quantitative King: How Renaissance Technologies Locks in Excess Returns Amid the 2025 Turmoil
TradingKey - Founded by mathematician James Simons, Renaissance Technologies LLC is a global leader in quantitative investing, renowned for its data-driven, innovative approach. The firm eschews traditional fundamental analysis, relying instead on advanced mathematical models
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing..jpg)
U.S. July CPI Commentary: Obstacles Cleared, Where Will U.S. Stocks Go Next?
TradingKey - On 12 August 2025, the United States released its Consumer Price Index (CPI) data for July. In terms of headline inflation, the CPI rose by 2.7% year-on-year in the month, slightly lower than the expected 2.8%. However, core CPI climbed 3.1% year-on-year, edging past the projected 3.0%.
